Parinda A. Mehta, MD
- Member, Division of Bone Marrow Transplantation and Immune Deficiency
- Professor, UC Department of Pediatrics
- parinda.mehta@cchmc.org
- Board Certified
About
BA: Parle College, Mumbai, India, 1988
MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993
Residency: Upstate Medical University, State University of New York, Syracuse, NY, 2002
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005
Certifications: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different? Transplantation and Cellular Therapy. 2019; 25(12):2416-2421.
Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Transplantation and Cellular Therapy. 2018; 24(12):e11-e19.
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer. 2018; 65(7):e27034.
Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Journal of Antimicrobial Chemotherapy. 2018; 73(6):1651-1658.
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report. Transplantation and Cellular Therapy. 2026; 32(5):580.e1-580.e18.
Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. Journal of Clinical Oncology. 2026; 44(11):1003-1015.
Radiation-Free Reduced-Intensity Conditioning Achieves Excellent Outcomes in Pediatric Severe Aplastic Anemia. Transplantation and Cellular Therapy. 2026; 32(2):s581.
Outcomes of Allogeneic Stem Cell Transplantation In the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia Based on Transplant Center: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Transplantation and Cellular Therapy. 2026; 32(2):s112.
Utilization of Intravenous Posaconazole in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy. 2025; 31(12):1033.e1-1033.e11.
Abatacept Prevents Severe Acute Graft-Versus-Host Disease Without Increasing Graft Failure Risk in Pediatric Bone Marrow Failure Syndromes. Pediatric Blood and Cancer. 2025; 72(12):e32085.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey